Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. According to the company, the session will be webcast and archived for at least thirty days.
Investors can access the live webcast and archived replay via the company’s Events page.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RPRX slipped 0.55% while key biotech peers were mixed: INSM (-6.97%), SMMT (-3.03%), INCY (-1.06%), BNTX (-0.95%), GMAB (+0.48%). No coordinated sector move is evident around this conference news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings results | Positive | +0.1% | Reported strong Q4 and 2025 growth with detailed 2026 Portfolio Receipts guidance. |
| Jan 20 | Earnings date set | Neutral | +1.6% | Announced timing and access details for Q4 and full‑year 2025 results call. |
| Jan 12 | Conference update | Positive | +0.2% | Outlined 2025 transaction activity, market share, growth metrics and 2026 milestones. |
| Jan 11 | Strategic partnership | Positive | +0.2% | Committed up to $500M to support Teva’s TEV-’408 development in vitiligo and celiac. |
| Jan 09 | Dividend increase | Positive | -0.2% | Announced first‑quarter 2026 dividend of $0.235, a 6.8% increase versus prior quarter. |
Recent fundamentally positive news (earnings, business updates, partnership, dividend increase) has usually seen small positive price reactions, with one noted divergence on the dividend hike.
Over recent months, Royalty Pharma reported strong 2025 results with Q4 Portfolio Receipts of $874 million and full‑year $3,254 million, plus 2026 guidance of $3,275M–$3,425M. It highlighted $4.7 billion of 2025 transactions and a first‑quarter 2026 dividend of $0.235 per share, a 6.8% increase. A Teva funding deal of up to $500 million and prior conference updates show an active capital deployment and investor‑engagement strategy, into which this TD Cowen conference appearance neatly fits.
Market Pulse Summary
This announcement outlines Royalty Pharma’s participation in TD Cowen’s 46th Annual Health Care Conference on March 3, 2026, with a webcast at 1:10 p.m. ET and at least 30 days of replay access. Against a backdrop of recent earnings strength, higher dividends, and active deal‑making, the conference primarily serves as an investor‑relations touchpoint. Investors may focus on any incremental commentary around capital deployment, portfolio performance, or previously disclosed 2026 guidance.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) present at TD Cowen’s 46th Annual Health Care Conference?
How can investors watch the Royalty Pharma (RPRX) webcast for the March 3, 2026 fireside chat?
Will Royalty Pharma (RPRX) archive the TD Cowen conference webcast and for how long?
Where is the Royalty Pharma (RPRX) webcast link located for the March 3 presentation?
What format is Royalty Pharma’s (RPRX) session at TD Cowen’s conference?
Will the Royalty Pharma (RPRX) webcast be available to view after the live event for international investors?
